KYMERA THERAPEUTICS, INC. Operating Lease Cost
KYMERA THERAPEUTICS, INC. (KYMR) reported Operating Lease Cost of $2.42 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-05
- KYMERA THERAPEUTICS, INC. operating lease, cost for the quarter ending 2026-06-30 was $2.42M, a 1.87% decline year-over-year.
- KYMERA THERAPEUTICS, INC. operating lease, cost for the quarter ending 2026-03-31 was $2.43M, a 1.78% decline year-over-year.
- KYMERA THERAPEUTICS, INC. operating lease, cost for the quarter ending 2025-12-31 was $2.44M, a 1.69% decline year-over-year.
- KYMERA THERAPEUTICS, INC. operating lease, cost for the quarter ending 2025-09-30 was $2.45M, a 1.64% decline year-over-year.
- KYMERA THERAPEUTICS, INC. operating lease, cost for fiscal 2025 was $9.83M, a 1.38% decline from fiscal 2024.
- KYMERA THERAPEUTICS, INC. operating lease, cost for fiscal 2024 was $9.97M, a 0.48% increase from fiscal 2023.
- KYMERA THERAPEUTICS, INC. operating lease, cost for fiscal 2023 was $9.92M, a 373.46% increase from fiscal 2022.
- KYMERA THERAPEUTICS, INC. operating lease, cost for fiscal 2022 was $2.10M, a 0.00% change from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.42M 10-Q · filed 2026-08-05 | $4.85M 10-Q · filed 2026-08-05 | $7.29M derived: sum of 3 quarters · filed 2026-08-05 | $9.74M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $2.43M 10-Q · filed 2026-04-30 | $4.87M derived: sum of 2 quarters · filed 2026-04-30 | $7.32M derived: sum of 3 quarters · filed 2026-04-30 | $9.79M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.89M derived: sum of 2 quarters · filed 2026-02-26 | $7.36M derived: sum of 3 quarters · filed 2026-08-05 | $9.83M 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.45M 10-Q · filed 2025-11-04 | $4.92M derived: sum of 2 quarters · filed 2026-08-05 | $7.39M 10-Q · filed 2025-11-04 | $9.87M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $2.46M 10-Q · filed 2026-08-05 | $4.94M 10-Q · filed 2026-08-05 | $7.42M derived: sum of 3 quarters · filed 2026-08-05 | $9.91M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $2.47M 10-Q · filed 2026-04-30 | $4.96M derived: sum of 2 quarters · filed 2026-04-30 | $7.45M derived: sum of 3 quarters · filed 2026-04-30 | $9.95M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $2.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.98M derived: sum of 2 quarters · filed 2026-02-26 | $7.48M derived: sum of 3 quarters · filed 2026-02-26 | $9.97M 10-K · filed 2026-02-26 |
| 2024-09-30 | $2.49M 10-Q · filed 2025-11-04 | $4.99M derived: sum of 2 quarters · filed 2025-11-04 | $7.48M 10-Q · filed 2025-11-04 | $9.84M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $2.50M 10-Q · filed 2025-08-11 | $4.99M 10-Q · filed 2025-08-11 | $7.35M derived: sum of 3 quarters · filed 2025-08-11 | $9.87M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $2.49M 10-Q · filed 2025-05-09 | $4.85M derived: sum of 2 quarters · filed 2025-05-09 | $7.37M derived: sum of 3 quarters · filed 2025-05-09 | $9.89M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $2.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $4.88M derived: sum of 2 quarters · filed 2025-02-27 | $7.40M derived: sum of 3 quarters · filed 2025-02-27 | $9.92M 10-K · filed 2025-02-27 |
| 2023-09-30 | $2.52M 10-Q · filed 2024-10-31 | $5.04M derived: sum of 2 quarters · filed 2024-10-31 | $7.56M 10-Q · filed 2024-10-31 | $8.09M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | $2.52M 10-Q · filed 2024-08-07 | $5.04M 10-Q · filed 2024-08-07 | $5.57M derived: sum of 3 quarters · filed 2024-08-07 | $6.09M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $2.52M 10-Q · filed 2024-05-02 | $3.04M derived: sum of 2 quarters · filed 2024-05-02 | $3.57M derived: sum of 3 quarters · filed 2024-05-02 | $4.09M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $524.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $1.05M derived: sum of 2 quarters · filed 2024-02-22 | $1.57M derived: sum of 3 quarters · filed 2024-02-22 | $2.10M 10-K · filed 2024-02-22 |
| 2022-09-30 | $524.00K 10-Q · filed 2023-11-02 | $1.05M derived: sum of 2 quarters · filed 2023-11-02 | $1.57M 10-Q · filed 2023-11-02 | $2.10M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $524.00K 10-Q · filed 2023-08-03 | $1.05M 10-Q · filed 2023-08-03 | $1.57M derived: sum of 3 quarters · filed 2023-08-03 | $2.10M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $524.00K 10-Q · filed 2023-05-04 | $1.05M derived: sum of 2 quarters · filed 2023-05-04 | $1.57M derived: sum of 3 quarters · filed 2023-05-04 | $2.10M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $524.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $1.05M derived: sum of 2 quarters · filed 2023-02-23 | $1.57M derived: sum of 3 quarters · filed 2023-02-23 | $2.10M 10-K · filed 2023-02-23 |
| 2021-09-30 | $524.00K 10-Q · filed 2022-11-03 | $1.05M derived: sum of 2 quarters · filed 2022-11-03 | $1.57M 10-Q · filed 2022-11-03 | $2.10M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $524.00K 10-Q · filed 2022-08-09 | $1.05M 10-Q · filed 2022-08-09 | $1.57M derived: sum of 3 quarters · filed 2022-08-09 | $2.18M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $524.00K 10-Q · filed 2022-05-03 | $1.05M derived: sum of 2 quarters · filed 2022-05-03 | $1.65M derived: sum of 3 quarters · filed 2022-05-03 | $2.33M derived: sum of 4 quarters · filed 2022-05-03 |
| 2020-12-31 | $524.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $1.13M derived: sum of 2 quarters · filed 2022-02-24 | $1.80M derived: sum of 3 quarters · filed 2022-02-24 | $2.72M 10-K · filed 2022-02-24 |
| 2020-09-30 | $606.00K 10-Q · filed 2021-11-10 | $1.28M derived: sum of 2 quarters · filed 2021-11-10 | $2.19M 10-Q · filed 2021-11-10 | $3.09M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $673.00K 10-Q · filed 2021-08-06 | $1.56M 10-Q · filed 2021-08-06 | $2.48M derived: sum of 3 quarters · filed 2021-08-06 | $2.73M derived: sum of 4 quarters · filed 2021-08-06 |
| 2020-03-31 | $889.00K 10-Q · filed 2021-05-06 | $1.81M derived: sum of 2 quarters · filed 2021-05-06 | $2.06M derived: sum of 3 quarters · filed 2021-05-06 | |
| 2019-12-31 | $923.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $1.17M derived: sum of 2 quarters · filed 2021-03-11 | $1.60M 10-K · filed 2021-03-11 | |
| 2019-09-30 | $247.00K 10-Q · filed 2020-11-05 | $674.00K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |